Genome transposable elements as drivers of inflammation in understudied skin types
Project Number3R01AR078306-04S1
Former Number5R01AR078306-03
Contact PI/Project LeaderBOTCHKAREV, VLADIMIR A Other PIs
Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
PROJECT SUMMARY
Ethnic disparities represent a significant problem in modern dermatology, and additional efforts are required
to better understand mechanisms underlying the development of skin diseases in patients with skin of color.
Inflammatory skin conditions (acne, atopic dermatitis, hidradenitis suppurativa) represent a group of
diseases, which disproportionally impact African American (AA) patients including children. Comparative
transcriptome analyses of the skin reveal higher expression of multiple inflammation-related genes in AA healthy
individuals compared to non-Hispanic White (NHW) individuals.
Regulation of expression of the genes involved in inflammatory skin response occurs at several levels
including signaling/transcription factor-mediated and epigenetic mechanisms. Transposable elements (TEs) are
repetitive mobile segments of DNA that constitute 44%-55% of mouse or human genomes. Inappropriate TE
activation has been implicated in pathogenesis of over 120 human diseases including autoimmune disorders.
Most TEs are transcriptionally inactive, while their aberrant activation result in a production of double-
stranded (ds) RNA and dsDNA triggering the dsRNA/DNA sensing mechanisms followed by anti-viral immune
response. In the epidermis, UV exposure activates transcription of endogenous retroviral sequences.
Endogenous retroviruses of the HERV-K and W families are significantly upregulated in psoriatic versus non-
lesional skin. However, contribution of TEs to regulation of skin inflammation in AA individuals remain unknown.
In this Administrative Supplement application to AR078306-03 grant, we will test a hypothesis that aberrant
activation of TEs in epidermal keratinocytes serve as critical determinant driving inflammatory skin response in
individuals with understudied skin types, while pharmacological inhibition of the TE transcription with the
nucleoside reverse transcriptase inhibitors provides a novel strategy for management of inflammatory skin
conditions in these individuals. This hypothesis will be addressed via two Specific Aims:
1. Perform comparative analyses of the landscapes of transposable element expression in human
epidermal keratinocytes between understudied skin types and NHW skin and correlate these data with
gene expression and patterns of active/repressive covalent DNA/histone modifications.
2. Define the effects of the inhibitors of dsRNA and dsDNA pathways on expression of inflammation-
associated genes in epidermal keratinocytes isolated from understudied skin types in 3D skin equivalent
culture and in experimental in vitro models of skin inflammation.
The generated outputs from this application will provide novel insights into fundamental mechanisms
regulating inflammation in understudied human skin types, as well as will promote the development of novel
paradigms for management of skin inflammatory responses in humans via modulation of TE activities.
Public Health Relevance Statement
PROJECT NARRATIVE
Transposable elements constitute a significant part of the non-coding genome, while their
inappropriate activation has been implicated in pathogenesis of over 120 human diseases
including autoimmune disorders. In this application, we will address the following questions:
1) Are there any differences in the expression of genome transposable elements between
epidermal keratinocytes isolated from the skin of African American, Hispanic and Asian origin and
non-Hispanic White origin, 2) Which mechanisms regulate transposable element silencing in
keratinocytes of different ethnic groups, and 3) Whether modulation of inflammatory response by
nucleoside reverse transcriptase inhibitors might serve as new approach for management of skin
inflammatory conditions in individuals with understudied skin types. The generated outputs on
this project will provide a platform for translation of these results into clinics and will promote the
development of novel therapeutic interventions, which hopefully could serve as new paradigm for
management of skin inflammatory conditions in patients with skin of color and their prevention.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
846
DUNS Number
604483045
UEI
FBYMGMHW4X95
Project Start Date
16-March-2021
Project End Date
31-January-2026
Budget Start Date
01-February-2024
Budget End Date
31-January-2025
Project Funding Information for 2024
Total Funding
$247,500
Direct Costs
$150,000
Indirect Costs
$97,500
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Arthritis and Musculoskeletal and Skin Diseases
$247,500
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3R01AR078306-04S1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3R01AR078306-04S1
Patents
No Patents information available for 3R01AR078306-04S1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3R01AR078306-04S1
Clinical Studies
No Clinical Studies information available for 3R01AR078306-04S1
News and More
Related News Releases
No news release information available for 3R01AR078306-04S1
History
No Historical information available for 3R01AR078306-04S1
Similar Projects
No Similar Projects information available for 3R01AR078306-04S1